Matt Miksic
Stock Analyst at Barclays
(3.95)
# 613
Out of 5,124 analysts
309
Total ratings
60.67%
Success rate
7.03%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $197 → $217 | $207.35 | +4.65% | 15 | Dec 30, 2025 | |
| EW Edwards Lifesciences | Maintains: Overweight | $99 → $103 | $85.33 | +20.71% | 31 | Dec 8, 2025 | |
| MDT Medtronic | Maintains: Overweight | $109 → $111 | $96.05 | +15.56% | 22 | Nov 20, 2025 | |
| OBIO Orchestra BioMed Holdings | Maintains: Overweight | $12 → $11 | $4.31 | +155.22% | 3 | Nov 12, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $51 → $55 | $21.55 | +155.22% | 8 | Nov 10, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $106 → $114 | $87.30 | +30.58% | 16 | Nov 10, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $301 → $316 | $282.92 | +11.69% | 11 | Nov 7, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Underweight | $105 → $104 | $90.02 | +15.53% | 9 | Nov 6, 2025 | |
| SENS Senseonics Holdings | Maintains: Overweight | $1.5 → $31 | $5.89 | +426.32% | 2 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $98 → $80 | $66.54 | +20.23% | 8 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $23 | $20.76 | +10.79% | 4 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $16.58 | +2.53% | 6 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $443 → $453 | $348.18 | +30.11% | 24 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $159 → $162 | $124.19 | +30.45% | 30 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $86 | $82.82 | +3.84% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $85 | $81.11 | +4.80% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $86 | $77.60 | +10.82% | 10 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $133 → $136 | $94.71 | +43.60% | 19 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3.5 | $0.98 | +258.97% | 1 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $55 → $58 | $60.67 | -4.40% | 8 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $36 | $19.50 | +84.62% | 22 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $21 | $14.79 | +41.99% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $241 | $194.94 | +23.63% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $684 → $635 | $561.98 | +12.99% | 7 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $4.92 | +347.15% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $76.82 | +30.17% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $156.03 | +167.90% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $17.69 | +58.28% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $11.27 | +494.50% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $2.52 | +18,947.62% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $12.01 | +624.40% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $4.64 | +439.37% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $6.48 | +38.89% | 1 | Dec 12, 2016 |
Johnson & Johnson
Dec 30, 2025
Maintains: Equal-Weight
Price Target: $197 → $217
Current: $207.35
Upside: +4.65%
Edwards Lifesciences
Dec 8, 2025
Maintains: Overweight
Price Target: $99 → $103
Current: $85.33
Upside: +20.71%
Medtronic
Nov 20, 2025
Maintains: Overweight
Price Target: $109 → $111
Current: $96.05
Upside: +15.56%
Orchestra BioMed Holdings
Nov 12, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $4.31
Upside: +155.22%
Tandem Diabetes Care
Nov 10, 2025
Maintains: Overweight
Price Target: $51 → $55
Current: $21.55
Upside: +155.22%
Globus Medical
Nov 10, 2025
Maintains: Overweight
Price Target: $106 → $114
Current: $87.30
Upside: +30.58%
Insulet
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $301 → $316
Current: $282.92
Upside: +11.69%
Zimmer Biomet Holdings
Nov 6, 2025
Maintains: Underweight
Price Target: $105 → $104
Current: $90.02
Upside: +15.53%
Senseonics Holdings
Nov 5, 2025
Maintains: Overweight
Price Target: $1.5 → $31
Current: $5.89
Upside: +426.32%
DexCom
Nov 3, 2025
Maintains: Equal-Weight
Price Target: $98 → $80
Current: $66.54
Upside: +20.23%
Nov 3, 2025
Maintains: Overweight
Price Target: $22 → $23
Current: $20.76
Upside: +10.79%
Oct 31, 2025
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $16.58
Upside: +2.53%
Oct 22, 2025
Maintains: Overweight
Price Target: $443 → $453
Current: $348.18
Upside: +30.11%
Oct 17, 2025
Maintains: Overweight
Price Target: $159 → $162
Current: $124.19
Upside: +30.45%
Oct 13, 2025
Initiates: Equal-Weight
Price Target: $86
Current: $82.82
Upside: +3.84%
Oct 13, 2025
Initiates: Overweight
Price Target: $85
Current: $81.11
Upside: +4.80%
Oct 13, 2025
Initiates: Equal-Weight
Price Target: $86
Current: $77.60
Upside: +10.82%
Oct 2, 2025
Maintains: Overweight
Price Target: $133 → $136
Current: $94.71
Upside: +43.60%
Aug 27, 2025
Initiates: Overweight
Price Target: $3.5
Current: $0.98
Upside: +258.97%
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $55 → $58
Current: $60.67
Upside: -4.40%
Aug 4, 2025
Maintains: Overweight
Price Target: $41 → $36
Current: $19.50
Upside: +84.62%
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $14.79
Upside: +41.99%
Jun 3, 2025
Maintains: Overweight
Price Target: $261 → $241
Current: $194.94
Upside: +23.63%
Apr 24, 2025
Maintains: Overweight
Price Target: $684 → $635
Current: $561.98
Upside: +12.99%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $4.92
Upside: +347.15%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $76.82
Upside: +30.17%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $156.03
Upside: +167.90%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $17.69
Upside: +58.28%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $11.27
Upside: +494.50%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $2.52
Upside: +18,947.62%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $12.01
Upside: +624.40%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $4.64
Upside: +439.37%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $6.48
Upside: +38.89%